RS53257B2 - Lentiviralni vektori pseudotipizirani sa omotačem od glikobelančevine iz sindbis-virusa - Google Patents

Lentiviralni vektori pseudotipizirani sa omotačem od glikobelančevine iz sindbis-virusa

Info

Publication number
RS53257B2
RS53257B2 RS20140158A RSP20140158A RS53257B2 RS 53257 B2 RS53257 B2 RS 53257B2 RS 20140158 A RS20140158 A RS 20140158A RS P20140158 A RSP20140158 A RS P20140158A RS 53257 B2 RS53257 B2 RS 53257B2
Authority
RS
Serbia
Prior art keywords
lentiviral vector
virus
polypeptide
antigen
seq
Prior art date
Application number
RS20140158A
Other languages
English (en)
Inventor
James M Allen
Hoeven Neal S Van
jin zhong Li
Derek D Sloan
Thomas W Dubensky Jr
Original Assignee
Immune Design Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42727669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS53257(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immune Design Corp filed Critical Immune Design Corp
Publication of RS53257B publication Critical patent/RS53257B/sr
Publication of RS53257B2 publication Critical patent/RS53257B2/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36145—Special targeting system for viral vectors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (23)

  1. Patentni zahtevi 1. Čestice lentiviralnog vektora, naznačene time, što obuhvataju: (a) omotač koji se sastoji od (i) E2 glikobelančevine iz Sindbis-virusa sa SEQ ID BR: 1 gde 160X je odsutna ili je neka amino-kiselina koja je različita od glutaminske kiseline, ili od varijante SEQ ID BR: 1 koja ima najmanje 80% identičnosti sa SEQ ID BR: 1 i gde 160X je odsutna ili je neka amino-kiselina koja je različita od glutaminske kiseline, koja je sposobna da inficira dendrite; pri čemu E2 nije deo fuzione belančevine sa E3 iz Sindbis-virusa; i (b) genom lentiviralnog vektora koji obuhvata jednu ili više sekvenci od interesa.
  2. 2. Čestica lentiviralnog vektora iz zahteva 1, naznačena time, što je u njoj 160X odsutna ili je glicin, alanin, valin, leucin ili izoleucin, na primer je izabrana iz glicina, valina, leucina ili izoleucina.
  3. 3. Čestica lentiviralnog vektora iz zahteva 1 ili 2, naznačena time, što varijanta E2 glikobelančevine ima najmanje jednu amino-kiselinu koja je promenjena sa ciljem da se smanji njen neto pozitivni naboj.
  4. 4. Čestica lentiviralnog vektora iz zahteva 3, naznačena time, što najmanje jedna aminokiselina koja treba da se promeni sa ciljem da se smanji neto pozitivni naboj je izabrana iz lizina 70, lizina 76 ili lizina 159 iz SEQ ID BR: 1, pri čemu su supstitucije preferirano nezavisno izabrane iz glutaminske kiseline ili asparaginske kiseline.
  5. 5. Čestica lentiviralnog vektora iz zahteva 1, naznačena time, što sekvenca E2 varijante sadrži amino-kiselinske ostatke 66 do 488 iz SEQ ID BR: 3, amino-kiselinske ostatke 66 do 488 iz SEQ ID BR: 4, ili amino-kiselinske ostatke 66 do 486 iz SEQ ID BR: 5; (varijante 1, 2 i 3).
  6. 6. Čestica lentiviralnog vektora iz zahteva 1-5, naznačena time, što predstavlja varijantu u kojoj sekvenca sa ostacima 71-75 iz SEQ ID BR: 1 nije promenjena ili ima jednu ili dve supstitucije koje ne utiču na sposobnost pomenute varijante da inficira DC, ali ne menjaju broj amino-kiselina u tom regionu.
  7. 7. Čestica lentiviralnog vektora iz bilo kojeg od zahteva od 1-6, naznačena time, što sekvenca od interesa eksprimira produkt koji je antigen iz agensa koji uzrokuje bolest ili iz bolesne ćelije.
  8. 8. Čestica lentiviralnog vektora iz bilo kojeg od zahteva od 1-6, naznačena time, što sekvenca od interesa kodira tumor-specifični antigen, ponekad NY-ESO-1, MAGE, MART-l/Melan-A, BAGE, RAGE, antigen iz linije melanocitnog melanoma, poput gp 100, gp75, mda-7, tirozinaze ili belančevine slične tirozinaze; antigen iz karcinoma bubrežnih ćelija, 5T4, SM22-alfa, karbonsku anhidrazu I, kartonsku anhidrazu IX (takođe poznatu kao G250), faktore koji se induciraju hipoksijom (ponekad, HIF-1 alfa ili HIF-2alfa), VEGF ili membranski antigen specifičan za prostatu (PSMA), antigen specifičan za prostatu (PSA), fosfati prostatne kiseline, šest-transmembranski epoitelijalni antigen iz prostate (STEAP), NKX3.1, epitop belančevina/peptida koji su dobiveni iz gena koji mutiraju u tumorskim ćelijama ili gena koji se transkribiraju u drugačijim nivoima u tumoru u odnosu na normalne ćelije, poput encima telomeraze, survivina, mezotelina, mutiranog ras, bcr/abl rearanžmana, Her2/neu, mutiranog ili divljeg-tipa p53, citohroma P450 1B1 , nenormalno eksprimiranih intronskih sekvenca poput N-acetilglukozaminiltransferaze-V; klonalni rearanžmani imunoglobulinskih gena koji generišu jedinstvene idiotipove mijeloma ili limfoma B-ćelija; epitop belančevina/peptida koji su dobiveni tokom onkoviralnih procesa, poput belančevine E6 ili E7 iz humanog papiloma-virusa; ili ne-mutirane onkofetalne belančevine sa tumorselektivnom ekspresijom, poput karcinoembrionskog antigena ili alfa-fetobelančevine.
  9. 9. Čestica lentiviralnog vektora iz bilo kojeg od zahteva od 1 - 7 , naznačena time, što sekvenca od interesa kodira antigen izveden iz virusa, poput antigena iz HIV ili SIV, polipeptida adenovirusa, polipeptida alfavirusa, polipeptida kalicivirusa, tj., antigen iz kapsida kalicivirusa, polipeptida koronavirusa, polipeptida distemper-virusa, polipeptida Ebola- virusa, polipeptida enterovirusa, polipeptida flavivirusa, polipeptida hepatitis virusa (AE), tj., antigen iz srži ili površine hepatitisa B, ili belančevine El ili E2 iz virusa hepatitisa C, srž, ili ne-strukturne belančevine, polipeptida herpesvirusa, tj., glikobelančevine iz herpessimpleks virusa ili virusa varicella-zoster, polipeptida virusa imunodificijencije, tj., omotač ili proteaza iz virusa humane imunodificijencije, polipeptida virusa infektivnog peritonitisa, polipeptida virusa influence, tj., hemaglutinin, neuraminidazu iz influence A; ili nukleobelančevina, polipeptida iz virusa leukemije, polipeptida Marburg-virusa, polipeptida ortomiksovirusa, polipeptida papiloma-virusa, polipeptida virusa parainfluence, tj., hemaglutinin/neuraminidaza, polipeptida paramiksovirusa, polipeptida parvovirusa, polipeptida pestivirusa, polipeptida pikoma-virusa, tj., polipeptida iz kapsida poliovirusa, polipeptida poks-virusa, tj., polipeptida vakcinija-virusa, polipeptida virusa besnila, tj., glikobelančevina G iz virusa besnila, polipeptida reovirusa, polipeptida retrovirusa, ili polipeptida rotavirusa.
  10. 10. Kompozicija koja obuhvata česticu lentiviralnog vektora iz bilo kojeg od zahteva od 1-9, naznačena time, što sadrži IU od najmanje 10<5>/mL.
  11. 11. Sistem za pakovanje lentiviralnog vektora za proizvodnju pseudotipizirane čestice lentiviralnog vektora iz bilo kojeg od zahteva od 1-9, ili kompozicija iz zahteva 10, naznačeni time, što obuhvataju: (i) prvi molekul nukleinske kiseline koji kodira E2 glikobelančevinu iz Sindbis-virusa iz zahteva 1 (a)(i), i; (ii) drugi molekul nukleinske kiseline koji kodira gag- i pol-belančevinu, (iii) treći molekul nukleinske kiseline koji kodira rev; (iv) genom lentiviralnog vektora koji sadrži sekvencu od interesa; i (v) ćeliju za pakovanje.
  12. 12. Sistem za pakovanje lentiviralnog vektora iz zahteva l1, naznačen time, što: (a) pol-belančevina sadrži ne-funkcionalnu integrazu; i/ili (b) pol-belančevina sadrži ne-funkcionalnu integrazu sa D64V mutacijom; i/ili (c) genom lentiviralnog vektora je takav da ne može da se integriše; i/ili (d) ćelija za pakovanje je stabilno transformisana sa (ii) i (iii); i/ili (e) ćelija za pakovanje je transformisana sa (i) i (iv).
  13. 13. Izolovan molekul nukleinske kiseline, naznačen time, što obuhvata nukleotidnu sekvencu koja kodira E2 glikobelančevinu ili varijantu iz zahteva 1 (a)(i), ili bilo kojeg od zahteva od
  14. 14. Molekul nukleinske kiseline iz zahteva 13, naznačen time, što pomenuta belančevina je E3/E2/6K/El-polibelančevina iz Sindbis-a koja se obrađuje na način da E2 belančevina nije deo fuzione belančevine sa E3 kada se ugradi u viralni omotač.
  15. 15. Molekul nukleinske kiseline iz zahteva 14, naznačen time, što E3 sekvenca odgovara (a) ostacima 1-65 iz SEQ ID BR: 20, ili (b) njena varijanta ima najmanje 80% identičnosti sa ostacima 1-65 iz SEQ ID BR: 20, pri čemu ostaci 62-65 su RSKR (SEQ ID BR: 27), a pomenuta varijanta je sposobna da se ugradi u pseudotipizirani viralni omotač.
  16. 16. Postupak za proizvodnju čestice lentiviralnog vektora iz bilo kojeg od zahteva od 1-9, ili kompozicija iz zahteva 10 koja sadrži kultiviranje lentiviralnog sistema iz zahteva 11.
  17. 17. Lentiviralna čestica iz bilo kojeg od zahteva od 1-9, ili kompozicija iz zahteva 10, naznačeni time, što genom lentiviralnog vektora (a) sadrži inaktivisano ili samo-inaktivirajuće 3' dugo terminalno ponavljanje (LTR); i/ili (b) obuhvata U3-element kojemu nedostaje najmanje: (i) sekvenca-pojačivač; (j) (ii) TATA-kutija (iii) Sp 1-mesto (iv) NK-kapa B-mesto i (v) polipurinski trakt (PPT); i/ili (c) obuhvata nukleotidnu sekvencu iz SEQ ID BR: 21, 22 ili 23; i/ili, (d) obuhvata nukleotidnu sekvencu koja kodira faktor za sazrevanje/stimulisanje dendrita.
  18. 18. Čestica lentiviralnog vektora u skladu sa bilo kojem od zahteva od 1-9, ili kompozicija iz zahteva 10, naznačeni time, što se koriste u postupku za tretman ljudskog ili životinjskog subjekta, pri čemu tretman ponekad obuhvata dostavu čestica lentiviralnog vektora u dendrite ex vivo.
  19. 19. Čestice lentiviralnog vektora prema bilo kojeg od zahteva od 1-9, ili kompozicija iz zahteva 10, naznačeni time, što se koriste za indukovanje antigen-specifičnog imuno odgovora, ponekad humoralnog odgovora i/ili ćelijskog odgovora.
  20. 20. Terapeutsku ili profilaktičku vakcinu, naznačena time, što obuhvata čestice lentiviralnog vektora iz bilo kojeg od zahteva od 1-9, ili kompoziciju iz zahteva 10, i neki farmaceutski prihvatljivi ekscipijent.
  21. 21. Terapeutska ili profilaktička vakcina u skladu sa zahtevom 20, naznačena time, što dodatno obuhvata neki dodatak.
  22. 22. Terapeutska ili profilaktička vakcina u skladu sa zahtevom 21, naznačena time, što pomenuti dodatak je neki dodatak sa formulom (I):
    gde Al i A2 su nezavisno izabrani iz grupe koja obuhvata vodonik, fosfat, i fosfatne soli, a ostaci R<1>, R<2>, R<3>, R<4>, R<5>i R<6>su nezavisno izabrani iz grupe ugljovodonika koji imaju 3 do 23 ugljenika, a su predstavljeni sa<C3-C23.>
  23. 23. Terapeutska ili profilaktička vakcina u skladu sa zahtevom 22, naznačena time, što (a) Al je fosfat ili fosfatna so, a A2 je vodonik, i (b) (i) R<1>, R<3>, R<5>i R<6>su C<11>-C<20>alkil, a R<2>i R<4>su C<12>-C<20>ugljovodonik; ili (ii) R<1>, R<3>, R<5>i R<6>su C11alkil, a R<2>i R<4>su C<13>ugljovodonik; ili (iii) R<1>, R<3>, R<5>i R<6>su undecil, a R<2>i R<4>su tridecil. Izdaje i štampa: Zavod za intelektualnu svojinu, Beograd, Kneginje Ljubice 5
RS20140158A 2009-07-24 2010-07-22 Lentiviralni vektori pseudotipizirani sa omotačem od glikobelančevine iz sindbis-virusa RS53257B2 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22849109P 2009-07-24 2009-07-24
EP10737715.2A EP2456786B2 (en) 2009-07-24 2010-07-22 Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein
PCT/US2010/042870 WO2011011584A1 (en) 2009-07-24 2010-07-22 Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein

Publications (2)

Publication Number Publication Date
RS53257B RS53257B (sr) 2014-08-29
RS53257B2 true RS53257B2 (sr) 2018-06-29

Family

ID=42727669

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20140158A RS53257B2 (sr) 2009-07-24 2010-07-22 Lentiviralni vektori pseudotipizirani sa omotačem od glikobelančevine iz sindbis-virusa
RS20181505A RS58042B1 (sr) 2009-07-24 2010-07-22 Neintegrišući lentivirusni vektori

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20181505A RS58042B1 (sr) 2009-07-24 2010-07-22 Neintegrišući lentivirusni vektori

Country Status (27)

Country Link
US (3) US20110064763A1 (sr)
EP (2) EP2770061B1 (sr)
JP (4) JP2013500015A (sr)
KR (1) KR101790187B1 (sr)
CN (1) CN102482329B (sr)
AU (1) AU2010276194B2 (sr)
BR (1) BR112012001653A2 (sr)
CA (1) CA2768938C (sr)
CY (1) CY1121159T1 (sr)
DK (2) DK2770061T3 (sr)
EA (1) EA032403B1 (sr)
ES (2) ES2702274T3 (sr)
HR (2) HRP20140327T4 (sr)
HU (1) HUE043032T2 (sr)
IL (1) IL217679A (sr)
LT (1) LT2770061T (sr)
ME (1) ME01720B (sr)
MX (1) MX2012001075A (sr)
NZ (1) NZ597804A (sr)
PL (2) PL2770061T3 (sr)
PT (2) PT2770061T (sr)
RS (2) RS53257B2 (sr)
SG (1) SG177744A1 (sr)
SI (2) SI2456786T2 (sr)
SM (2) SMT201800656T1 (sr)
TR (1) TR201819229T4 (sr)
WO (1) WO2011011584A1 (sr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2657737T3 (es) * 2009-07-15 2018-03-06 Calimmune Inc. Vector dual para la inhibición del virus de la inmunodeficiencia humana
WO2012112691A1 (en) * 2011-02-15 2012-08-23 Immune Design Corp. Methods for enhancing immunogen specific immune responses by vectored vaccines
EA027236B1 (ru) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
WO2013116656A1 (en) * 2012-02-03 2013-08-08 Emory University Immunostimulatory compositions, particles, and uses related thereto
EP2844746A4 (en) 2012-03-26 2016-07-20 Univ California PSEUDOTYPIZED LENTIVIRES WITH NIPAH VIRUS COVERS AND METHOD OF USE THEREOF
US9713635B2 (en) * 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
WO2013149167A1 (en) * 2012-03-30 2013-10-03 Immune Design Corp. Lentiviral vector particles having improved transduction efficiency for cells expressing dc- sign
US8323662B1 (en) * 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
HRP20181102T1 (hr) 2012-05-16 2018-09-07 Immune Design Corp Cjepiva za hsv-2
EP2943203A4 (en) * 2013-01-11 2016-08-24 Scripps Research Inst METHOD AND COMPOSITIONS FOR INCREASING THE TRANSDUCTION EFFICIENCY OF RETROVIRAL VECTORS
GB201308772D0 (en) * 2013-05-15 2013-06-26 Imp Innovations Ltd Vectors
SMT202000531T1 (it) 2014-03-09 2020-11-10 Univ Pennsylvania Composizioni utili in trattamento di deficit di ornitina transcarbamilasi(otc)
KR20170032373A (ko) 2014-07-15 2017-03-22 이뮨 디자인 코포레이션 Tlr4 작용제 보조제 및 렌티바이러스 벡터를 이용한 프라임-부스트 요법
WO2016118715A1 (en) * 2015-01-21 2016-07-28 Cornell University Viral vectors for prophylaxis and therapy of hemoglobinopathies
US20180112180A1 (en) * 2015-01-26 2018-04-26 Fate Therapeutics, Inc. Cells with increased immuno-regulatory properties and methods for their use and manufacture
CN114262380A (zh) 2015-03-18 2022-04-01 欧姆尼赛特有限公司 包含经修饰的α病毒表面糖蛋白与肿瘤相关抗原的融合蛋白及其方法
DK3283658T3 (da) 2015-05-18 2020-05-18 Calimmune Inc Fremgangsmåder til at diskriminere mellem HIV-1 og lentivirus-vektorer
US20190119350A1 (en) 2015-09-09 2019-04-25 Immune Design Corp. Ny-eso-1 specific tcrs and methods of use thereof
WO2017083291A1 (en) * 2015-11-09 2017-05-18 Immune Design Corp. Compositions comprising lentiviral vectors expressing il-12 and methods of use thereof
AU2016354102B2 (en) 2015-11-09 2022-05-12 Immune Design Corp. A retroviral vector for the administration and expression of replicon RNA expressing heterologous nucleic acids
JP2019509275A (ja) * 2016-02-23 2019-04-04 イミューン デザイン コーポレイション マルチゲノムレトロウイルスベクター調製物ならびにそれらを産生および使用するための方法およびシステム
WO2017152042A2 (en) * 2016-03-04 2017-09-08 New York University Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity
MX2018012472A (es) 2016-04-15 2019-08-12 Alpine Immune Sciences Inc Proteinas inmunomoduladoras variantes de ligando icos y sus usos.
WO2017181152A2 (en) 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
EP3235908A1 (en) 2016-04-21 2017-10-25 Ecole Normale Superieure De Lyon Methods for selectively modulating the activity of distinct subtypes of cells
EP3235828A1 (en) * 2016-04-21 2017-10-25 Genethon Stable pseudotyped lentiviral particles and uses thereof
WO2018022946A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
WO2018075978A1 (en) 2016-10-20 2018-04-26 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
WO2018148180A2 (en) 2017-02-07 2018-08-16 Immune Design Corp. Materials and methods for identifying and treating cancer patients
SG11201907769XA (en) 2017-03-16 2019-09-27 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
KR20190141146A (ko) 2017-03-16 2019-12-23 알파인 이뮨 사이언시즈, 인코포레이티드 Pd-l2 변이체 면역조절 단백질 및 그의 용도
EP3596116B1 (en) 2017-03-16 2023-09-06 Alpine Immune Sciences, Inc. Pd-l1 variant immunomodulatory proteins and uses thereof
CA3062426A1 (en) 2017-05-08 2018-11-15 Flagship Pioneering Innovations V, Inc. Compositions for facilitating membrane fusion and uses thereof
BR112020007542A2 (pt) 2017-10-18 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras ligantes de icos variantes e composições e métodos relacionados
AU2019205273B2 (en) 2018-01-03 2024-04-04 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
US11116833B2 (en) * 2018-02-08 2021-09-14 George Mason University Method and system for inactivating virus infectivity for producing live-attenuated vaccines
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
CN112955174A (zh) 2018-07-09 2021-06-11 旗舰先锋创新V股份有限公司 融合剂脂质体组合物和其用途
US12241079B2 (en) 2018-09-14 2025-03-04 The Children's Hospital Of Philadelphia Compositions and methods for hemoglobin production
CN113631718A (zh) 2018-11-14 2021-11-09 旗舰先锋创新V股份有限公司 用于特定隔室货物递送的组合物和方法
JP7520008B2 (ja) * 2018-11-23 2024-07-22 ビラ セラピューティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｖｓｖキメラベクター
CA3120868A1 (en) 2018-11-30 2020-06-04 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
US20220364119A1 (en) 2019-06-14 2022-11-17 The J. David Gladstone Institutes, a testamentary trust established under the Will of J.David Gladst Compositions and methods for treating an immunodeficiency virus infection with a therapeutic interfering particle
WO2021022308A2 (en) * 2019-08-01 2021-02-04 The Regents Of The University Of California Non-viral transgenesis
CN110982842B (zh) * 2019-12-31 2023-04-18 山西大学 一种慢病毒表达载体的设计及应用
CA3185952A1 (en) * 2020-07-15 2022-01-20 Pierre Charneau Sars-cov-2 immunogenic compositions, vaccines, and methods
KR20240028975A (ko) 2021-04-08 2024-03-05 사나 바이오테크놀로지, 인크. Cd8-특이적 항체 구조체들 및 이의 조성물
KR20240099340A (ko) * 2021-10-25 2024-06-28 젠비보, 인크. 치료제 또는 백신 전달을 위한 조성물 및 방법
US20230340627A1 (en) * 2022-04-05 2023-10-26 Bio-Rad Laboratories, Inc. Analysis of viral particles by digital assay
US20250302998A1 (en) 2022-05-09 2025-10-02 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
EP4536836A1 (en) 2022-06-07 2025-04-16 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2025106748A1 (en) * 2023-11-15 2025-05-22 Genvivo, Inc. Compositions and methods for therapeutic delivery

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4569794A (en) 1984-12-05 1986-02-11 Eli Lilly And Company Process for purifying proteins and compounds useful in such process
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
ATE112314T1 (de) 1988-05-17 1994-10-15 Lubrizol Genetics Inc Pflanzliches ubiquitinpromotorsystem.
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US5298420A (en) 1990-08-03 1994-03-29 Tanox Biosystems, Inc. Antibodies specific for isotype specific domains of human IgM and human IgG expressed or the B cell surface
TW279133B (sr) 1990-12-13 1996-06-21 Elan Med Tech
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
DE69333115D1 (de) 1992-09-22 2003-08-28 Biofocus Discovery Ltd Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren
US6534051B1 (en) 1992-11-20 2003-03-18 University Of Medicine And Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
US5279552A (en) 1993-01-11 1994-01-18 Anton Magnet Intradermal injection device
US5997501A (en) 1993-11-18 1999-12-07 Elan Corporation, Plc Intradermal drug delivery device
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5660835A (en) 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
CA2224907A1 (en) 1995-07-25 1997-02-13 Introgene B.V. Methods and means for targeted gene delivery
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
FR2747046B1 (fr) 1996-04-05 1998-06-19 Univ Paris Curie Nouveaux vaccins issus de plasmovirus
WO1998032869A1 (en) 1997-01-29 1998-07-30 Neurosearch A/S Expression vectors and methods for in vivo expression of therapeutic polypeptides
US6432699B1 (en) * 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
US6531123B1 (en) 1997-05-01 2003-03-11 Lung-Ji Chang Lentiviral vectors
ZA988446B (en) 1997-09-18 2000-03-22 Res Dev Foundation Production of vaccines using arthropod vectored viruses.
WO1999013905A1 (en) 1997-09-18 1999-03-25 The Trustees Of The University Of Pennsylvania Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
US7078483B2 (en) 1998-04-29 2006-07-18 University Of Southern California Retroviral vectors including modified envelope escort proteins
DE69941049D1 (de) * 1998-05-22 2009-08-13 Oxford Biomedica Ltd Retrovirales verabreichungssystem
WO2000055378A1 (en) * 1999-03-16 2000-09-21 Dana-Farber Cancer Institute, Inc. Lentiviral vector system for high quantity screening
DE60044125D1 (de) 1999-04-14 2010-05-20 Novartis Vaccines & Diagnostic Zusammensetzungen und verfahren zur auslösung einer immunantwort auf basis alphavirus-vektoren-systeme
EP1046651A1 (en) 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition and method for modulating dendritic cell-T interaction
CA2392010A1 (en) 1999-08-27 2001-03-08 Regents Of The University Of California Use of lentiviral vectors for antigen presentation in dendritic cells
PT1221968E (pt) 1999-10-13 2010-04-16 Novartis Vaccines & Diagnostic Processo de obtenção de respostas imunes celulares de proteínas
US20020193740A1 (en) 1999-10-14 2002-12-19 Alchas Paul G. Method of intradermally injecting substances
US6776776B2 (en) 1999-10-14 2004-08-17 Becton, Dickinson And Company Prefillable intradermal delivery device
US7241275B2 (en) 1999-10-14 2007-07-10 Becton, Dickinson And Company Intradermal needle
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
US6569143B2 (en) 1999-10-14 2003-05-27 Becton, Dickinson And Company Method of intradermally injecting substances
US6627442B1 (en) * 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
EP1368058A4 (en) * 2001-03-02 2005-01-12 Merck & Co Inc VIRAL REPORTER PARTICLES
WO2002101057A1 (fr) * 2001-06-08 2002-12-19 Dnavec Research Inc. Transfert genique dans des cellules souches embryonnaires de primate a l'aide d'un virus de l'immunodeficience simienne de pseudo type vsv-g utilise comme vecteur
JP4344858B2 (ja) 2001-09-13 2009-10-14 カリフォルニア インスティチュート オブ テクノロジー 細胞内で抗ウイルス性小ｒｎａ分子を発現させる方法
EP1451316B1 (en) 2001-09-13 2014-08-06 California Institute Of Technology Method for producing transgenic birds
US7737124B2 (en) 2001-09-13 2010-06-15 California Institute Of Technology Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
US7195916B2 (en) 2001-09-13 2007-03-27 California Institute Of Technology Method for expression of small antiviral RNA molecules within a cell
US6971999B2 (en) 2001-11-14 2005-12-06 Medical Instill Technologies, Inc. Intradermal delivery device and method
BRPI0307434B8 (pt) 2002-02-04 2021-06-22 Becton Dickinson Co dispositivo para aplicar ou retirar uma substância através da pele.
US7115108B2 (en) 2002-04-02 2006-10-03 Becton, Dickinson And Company Method and device for intradermally delivering a substance
US7047070B2 (en) 2002-04-02 2006-05-16 Becton, Dickinson And Company Valved intradermal delivery device and method of intradermally delivering a substance to a patient
US6780171B2 (en) 2002-04-02 2004-08-24 Becton, Dickinson And Company Intradermal delivery device
JP4343708B2 (ja) * 2002-04-26 2009-10-14 アンスティテュ ナシナル ドゥ ラ サントゥ エ ドゥ ラ ルシェルシェ メディカル−イ．エヌ．エス．ウ．エール．エム． 改良型キメラ糖タンパク質と、類型化されたレンチウイルス
US7455833B2 (en) 2002-07-15 2008-11-25 Board Of Regents, The University Of Texas System Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids
EP1535627B1 (en) 2002-08-16 2008-07-09 Japan Science and Technology Agency Recombinant bcg vaccine
AU2003297474A1 (en) 2002-12-18 2004-07-14 Salk Institute For Biological Studies Methods of inhibiting gene expression by rna interference
US7090837B2 (en) 2003-01-21 2006-08-15 The Salk Institute For Biological Studies Compositions and methods for tissue specific targeting of lentivirus vectors
US20050112139A1 (en) 2003-10-23 2005-05-26 Nmk Research, Llc Immunogenic composition and method of developing a vaccine based on factor H binding sites
US7108679B2 (en) 2004-03-11 2006-09-19 Becton, Dickinson And Company Intradermal syringe and needle assembly
WO2005113584A1 (en) * 2004-04-29 2005-12-01 Board Of Regents, University Of Texas System Methods and compositions comprising protein l immunoglobulin binding domains for cell-specific targeting
US20080227736A1 (en) 2004-06-03 2008-09-18 Regents Of The University Of California, Targeting Pseudotyped Retroviral Vectors
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
WO2006031996A2 (en) * 2004-09-14 2006-03-23 University Of Pittsburgh Of The Commonwealth System Of Higher Education Targeting viruses using a modified sindbis glycoprotein
RU2007134371A (ru) * 2005-02-16 2009-03-27 Лентиджен Корпорейшн (Us) Лентивирусные векторы и их применение
EP1885186B1 (en) 2005-06-01 2015-09-02 California Institute Of Technology Method of targeted gene delivery using viral vectors
US8329162B2 (en) * 2006-07-21 2012-12-11 California Institute Of Technology Targeted gene delivery for dendritic cell vaccination
PL2068918T5 (pl) 2006-09-26 2024-12-02 Access To Advanced Health Institute Kompozycja szczepionki zawierająca syntetyczny adiuwant
WO2009035528A2 (en) 2007-09-07 2009-03-19 University Of Georgia Research Foundation, Inc. Synthetic lipid a derivative
PL2222861T3 (pl) 2007-12-11 2018-04-30 The University Of North Carolina At Chapel Hill Wektory retrowirusowe ze zmodyfikowanym odcinkiem polipurynowym

Also Published As

Publication number Publication date
US20120039932A1 (en) 2012-02-16
SI2770061T1 (sl) 2019-02-28
TR201819229T4 (tr) 2019-01-21
AU2010276194B2 (en) 2012-02-02
CY1121159T1 (el) 2020-05-29
DK2770061T3 (en) 2019-01-07
SG177744A1 (en) 2012-02-28
EP2456786B1 (en) 2014-01-08
CA2768938A1 (en) 2011-01-27
HUE043032T2 (hu) 2019-07-29
HRP20140327T1 (hr) 2014-05-09
PT2456786E (pt) 2014-03-25
IL217679A (en) 2016-09-29
DK2456786T3 (en) 2014-03-24
SI2456786T2 (sl) 2017-08-31
US8187872B2 (en) 2012-05-29
EA032403B1 (ru) 2019-05-31
US20160076055A1 (en) 2016-03-17
JP6701280B2 (ja) 2020-05-27
JP2013500015A (ja) 2013-01-07
KR20120068838A (ko) 2012-06-27
PL2456786T5 (pl) 2017-10-31
JP2015109853A (ja) 2015-06-18
EA201270191A1 (ru) 2012-12-28
PT2770061T (pt) 2018-12-24
AU2010276194A1 (en) 2011-11-24
EP2456786B2 (en) 2017-04-19
HK1201557A1 (en) 2015-09-04
EP2770061B1 (en) 2018-10-24
US20110064763A1 (en) 2011-03-17
CN102482329B (zh) 2017-11-14
DK2456786T4 (en) 2017-08-07
CN102482329A (zh) 2012-05-30
ES2455544T5 (es) 2017-08-16
KR101790187B1 (ko) 2017-10-25
JP6170952B2 (ja) 2017-07-26
JP2017060535A (ja) 2017-03-30
ES2455544T3 (es) 2014-04-16
PL2456786T3 (pl) 2014-06-30
HRP20140327T4 (hr) 2017-11-03
CA2768938C (en) 2019-05-14
LT2770061T (lt) 2018-12-27
SMT201400041B (it) 2014-05-07
ES2702274T3 (es) 2019-02-28
MX2012001075A (es) 2012-05-22
JP2018198616A (ja) 2018-12-20
WO2011011584A1 (en) 2011-01-27
HRP20181996T1 (hr) 2019-03-22
PL2770061T3 (pl) 2019-02-28
BR112012001653A2 (pt) 2016-11-08
NZ597804A (en) 2013-10-25
RS53257B (sr) 2014-08-29
EP2770061A1 (en) 2014-08-27
EP2456786A1 (en) 2012-05-30
SMT201800656T1 (it) 2019-01-11
ME01720B (me) 2014-09-20
SI2456786T1 (sl) 2014-05-30
RS58042B1 (sr) 2019-02-28

Similar Documents

Publication Publication Date Title
RS53257B2 (sr) Lentiviralni vektori pseudotipizirani sa omotačem od glikobelančevine iz sindbis-virusa
JP7250878B2 (ja) 新規多価ナノ粒子に基づくワクチン
ES3041285T3 (en) A vaccine for use in the prophylaxis and/or treatment of a disease
Kaufmann et al. Virus chimeras for gene therapy, vaccination, and oncolysis: adenoviruses and beyond
JP6324725B2 (ja) 発現系
JP2015512263A5 (sr)
JP2004508808A5 (sr)
JP2013500015A5 (sr)
Grasso et al. Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein
WO2010040023A2 (en) Methods and compositions for protein delivery
Bellier et al. DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant
RU2015155821A (ru) Вакцины против малярии
JP2015096070A5 (sr)
JP2020502262A5 (sr)
CN103347892A (zh) 单体和多聚体免疫原性肽
Schweneker et al. Recombinant modified vaccinia virus Ankara generating Ebola virus-like particles
WO2014205579A4 (en) Modified matrix proteins of vesicular stomatitis virus
ES2683820T3 (es) Uso de proteínas GAG no de subtipo B para encapsidación lentiviral
Lu Combination DNA plus protein HIV vaccines
Deng et al. Induction of broadly neutralising HCV antibodies in mice by integration-deficient lentiviral vector-based pseudotyped particles
US20220380412A1 (en) Compositions comprising v2 opt hiv envelopes
WO2001070262A3 (en) A method for generating immunogens that elicit neutralizing antibodies against fusion-active regions of hiv envelope proteins
RU2020125098A (ru) Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита
JP2009522368A5 (sr)
US20230302083A1 (en) Highly-networked coronavirus immunogen composition